RxDoctor Payments Data

Michael Gebel, MD

Neurology · Fernandina Beach, FLNPI 1184625329

Payments from drug & device makers

$7,421in general payments, 2019–2025

Across 311 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$621
  • UCB, Inc.$408
  • Lilly USA, LLC$359
  • Lundbeck LLC$356
  • Amgen$307
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$7,421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,421 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$325,232
Medicare patients
860
Services billed
17,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$197,307
Gamunex-CImmune Globul G/Gly/Iga Avg 4620$55,793
Nurtec OdtRimegepant Sulfate26$27,002
NuedextaDextromethorphan Hbr/Quinidine13$18,681
BotoxOnabotulinumtoxina16$17,837
Glatiramer Acetate12$16,936
QuliptaAtogepant13$16,267
Aimovig AutoinjectorErenumab-Aooe13$10,087
Memantine Hcl270$8,999
Emgality SyringeGalcanezumab-Gnlm12$8,714
Rivastigmine13$6,810
Propranolol Hcl ErPropranolol Hcl164$5,475
Donepezil Hcl334$4,245
Carbamazepine ErCarbamazepine53$4,190
Levetiracetam112$3,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$51$197,30713 claims
Grifols USA, LLCGamunex-C$57$55,79320 claims
AbbVieBotox, Qulipta$1,209$34,10429 claims
PfizerNurtec Odt$150$27,00226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →